Pharmion Vidaza Clears FDA With Full Approval For Bone Marrow Disorder
Executive Summary
Pharmion plans to launch Vidaza for the treatment of myelodysplastic syndromes in July, following FDA approval May 19
You may also be interested in...
MGI Dacogen Launch Plans Stress Efficacy Profile, Treatment Duration
MGI will highlight the efficacy profile of its myelodysplastic syndromes therapy Dacogen when detailing decitabine to oncologists
MGI Dacogen Launch Plans Stress Efficacy Profile, Treatment Duration
MGI will highlight the efficacy profile of its myelodysplastic syndromes therapy Dacogen when detailing decitabine to oncologists
MGI Dacogen Dosing Strategy Will Consider Reimbursement, Convenience
MGI Pharma is evaluating more convenient dosing strategies for its oncologic Dacogen in patients with myelodysplastic syndromes